The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner.

Arce M, Huang H, Rorsman C, Erzar I, Oldenburg J, Sun Y, Smith R, Onyeogaziri FC, Barbera S, Ahlstrand FC, Ranefall P, Klemm A, Richards M, Dimberg A, Claesson-Welsh L, Magnusson PU

Open source

DOI: 10.1126/scitranslmed.adr0448
Published: 2026 Oct 21
Container: Science translational medicine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1126/scitranslmed.adr0448,
  title = {The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner.},
  author = {Arce M and Huang H and Rorsman C and Erzar I and Oldenburg J and Sun Y and Smith R and Onyeogaziri FC and Barbera S and Ahlstrand FC and Ranefall P and Klemm A and Richards M and Dimberg A and Claesson-Welsh L and Magnusson PU},
  year = {2026},
  journal = {Science translational medicine},
  doi = {10.1126/scitranslmed.adr0448},
  url = {https://doi.org/10.1126/scitranslmed.adr0448}
}

RIS

TY  - JOUR
TI  - The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner.
AU  - Arce M
AU  - Huang H
AU  - Rorsman C
AU  - Erzar I
AU  - Oldenburg J
AU  - Sun Y
AU  - Smith R
AU  - Onyeogaziri FC
AU  - Barbera S
AU  - Ahlstrand FC
AU  - Ranefall P
AU  - Klemm A
AU  - Richards M
AU  - Dimberg A
AU  - Claesson-Welsh L
AU  - Magnusson PU
PY  - 2026
JO  - Science translational medicine
DO  - 10.1126/scitranslmed.adr0448
UR  - https://doi.org/10.1126/scitranslmed.adr0448
ER  -

APA

M, A., H, H., C, R., I, E., J, O., Y, S., R, S., FC, O., S, B., FC, A., P, R., A, K., M, R., A, D., L, C., & PU, M. (2026). The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner.. Science translational medicine. https://doi.org/10.1126/scitranslmed.adr0448

Source records

pubmed · retrieved 2026-11-10T10:21:54.017Z
europe-pmc · retrieved 2026-11-10T10:21:54.014Z